Innovent Bio pockets HK$2.4bn from top-up

Jonathan Breen

October 04, 2019 08:00 am

unilab_Adobe_230x150 — Life scientists researching in laboratory. Female young scientist and her post doctoral supervisor microscoping in their working environment. Healthcare and biotechnology. | kasto - stock.adobe.com

Chinese biotechnology firm Innovent Biologics has raised HK$2.39bn ($304.3m) after selling a chunk of stock through a top-up placement.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity China Hong Kong SAR Asia Follow-ons and Rights Issues Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Follow-ons and Rights issues Emerging Markets SRI Goldman Sachs

JB

Jonathan Breen

Equities editor GlobalCapital Asia